Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

A Phase Two Randomised Controlled Trial of Belimumab in Kidney Transplant Recipients Demonstrates Comparable Safety, a Reduction in De Novo Antibody Production and an Increase in Regulatory B Cells.


ABSTRACT: There is an urgent unmet need in solid organ transplantation for immunotherapeutic strategies that target B cells and plasma cells, ideally without increasing infectious complications. We conducted a phase 2 double-blind randomised placebo-controlled trial to assess the safety and potential efficacy of an anti-BLyS antibody, belimumab, in addition to standard of care immunosuppression post-kidney transplantation.

ORGANISM(S): Homo sapiens

SUBMITTER: Paul Wilson 

PROVIDER: E-MTAB-5906 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2010-11-01 | E-GEOD-22459 | biostudies-arrayexpress
2013-10-30 | E-GEOD-51388 | biostudies-arrayexpress
2021-09-09 | PXD019284 | Pride
2013-01-29 | E-GEOD-36539 | biostudies-arrayexpress
2020-10-20 | PXD021507 | Pride
2015-07-31 | E-GEOD-48250 | biostudies-arrayexpress
2011-02-16 | E-GEOD-20427 | biostudies-arrayexpress
2024-02-22 | E-MTAB-12751 | biostudies-arrayexpress
2016-07-20 | E-GEOD-57387 | biostudies-arrayexpress
2013-05-23 | E-GEOD-47199 | biostudies-arrayexpress